India's Macleods Pharma to invest $25 million in production in Russia; Ferring to start manufacturing
Indian drugmaker Mаcleods Pharmaceuticals plans to invest up to 700 million roubles (around $25 million) in the construction of a plant for the production of antituberculous drugs in Russia’s Belgorod region by 2016.
The project is expected to be implemented by the local Advanced Trading company, an official supplier of Mаcleods drugs in the Russian market, which currently accounts for 25% of the Russian market of antituberculous drugs.
According to Sergey Mironov, head of Advanced Trading, the new plant will focus on the production of life-saving medicines, which are expected to be in high demand in the Russian market. At the initial stage the new plant will focus on the production of anti-tuberculosis medicines, while later the production range is expected to be expanded.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze